CAPR

Capricor Therapeutics Inc

Add to Watchlist

Advanced Chart

7.015

-0.155(-2.162%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

7.230

Open

7.110

VWAP

7.02

Vol

1.03M

Mkt Cap

320.70M

Low

6.940

Amount

7.27M

EV/EBITDA(TTM)

Total Shares

31.98M

208.37M

EV/OCF(TTM)

P/S(TTM)

22.62

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

480.00K

-78.78%

778.00K

-80.41%

Estimates Revision

The market is revising Downward the revenue expectations for Capricor Therapeutics, Inc. (CAPR) for FY2025, with the revenue forecasts being adjusted by -98.85% over the past three months. During the same period, the stock price has changed by -36.92%.

Revenue Estimates for FY2025

Revise Downward

-98.85%

In Past 3 Month

Stock Price

Go Down

-36.92%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast CAPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAPR is 19.90 USD with a low forecast of 8.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

Current: 7.015

Low

8.00

Averages

19.90

High

29.00

Current: 7.015

Low

8.00

Averages

19.90

High

29.00

Alliance Global Partners

Buy

maintain

$20 -> $16

2025-07-14

Reason

Alliance Global Partners

Price Target

$20 -> $16

2025-07-14

maintain

Buy

Reason

Alliance Global Partners lowered the firm's price target on Capricor Therapeutics to $16 from $20 and keeps a Buy rating on the shares after the company received a complete response letter from the FDA for deramiocel. The firm believes changes in the FDA administration most likely unfavorably impacted the company's application filing. However, Capricor's HOPE-3 trial results announcement in Q3 "may change FDA's outlook for the better," the analyst tells investors in a research note.

Roth Capital

Buy

downgrade

$31 -> $12

2025-07-14

Reason

Roth Capital

Price Target

$31 -> $12

2025-07-14

downgrade

Buy

Reason

Roth Capital lowered the firm's price target on Capricor Therapeutics to $12 from $31 and keeps a Buy rating on the shares. The FDA's Complete Response Letter - CRL - for Deramiocel well ahead of the PDUFA timeline of August 31 was a "surprise" as all eyes now turn to HOPE-3 top-line data expected in Q3, though the firm still expects positive HOPE-3 data and potential BLA approval in mid-2026, the analyst tells investors in a research note.

H.C. Wainwright

Joseph Pantginis

Buy

downgrade

$77 -> $24

2025-07-11

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

$77 -> $24

2025-07-11

downgrade

Buy

Reason

H.C. Wainwright analyst Joseph Pantginis lowered the firm's price target on Capricor Therapeutics to $24 from $77 and keeps a Buy rating on the shares after the company received a complete response letter from the FDA for deramiocel, its cell therapy candidate for the treatment of cardiomyopathy in Duchenne muscular dystrophy patients. The firm does not see the CRL "as the end of the story." The FDA offered Capricor the opportunity to request a Type A meeting, and H.C. Wainwright's positive thesis on deramiocel being approved for DMD cardiomyopathy following resubmission remains unchanged, the analyst tells investors in a research note. The firm pushed out the approval year for deramiocel to 2026 from 2025.

JonesResearch

Buy

maintain

$29

2025-07-11

Reason

JonesResearch

Price Target

$29

2025-07-11

maintain

Buy

Reason

JonesResearch keeps a Buy rating on Capricor Therapeutics with a $29 price target after the FDA issued a complete response letter for deramiocel in Duchenne muscular dystrophy. The firm says Deramiocel is a cell therapy and with 700 infusions, there have been no major safety events other than hypersensitivity in early stages. It believes Capricor's ongoing Phase 3 study, with data expected in Q3, should support resubmission to the FDA this year. Jones previously said that approval in August was unlikely. Capricor in morning trading is down 27% to $8.30.

Cantor Fitzgerald

Overweight

downgrade

$30 -> $22

2025-07-11

Reason

Cantor Fitzgerald

Price Target

$30 -> $22

2025-07-11

downgrade

Overweight

Reason

Cantor Fitzgerald lowered the firm's price target on Capricor Therapeutics to $22 from $30 and keeps an Overweight rating on the shares. The firm views the complete response letter for deramiocel as a "disappointing setback." However, the "binary nature" of the upcoming HOPE-3 data makes Capricor's risk/reward "quite interesting," the analyst tells investors in a research note. Cantor believes that if the HOPE-3 study is successful, the "argument for approval can grow substantially."

Piper Sandler

Edward Tenthoff

Overweight

downgrade

$43 -> $20

2025-07-11

Reason

Piper Sandler

Edward Tenthoff

Price Target

$43 -> $20

2025-07-11

downgrade

Overweight

Reason

Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Capricor Therapeutics to $20 from $43 and keeps an Overweight rating on the shares after the FDA issued a complete response letter for deramiocel in Duchenne muscular dystrophy. The firm believes Capricor could still win approval of cell therapy in 2026 and notes the company remains eligible for an $80M approval milestone from Nippon Shinyaku.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Capricor Therapeutics Inc (CAPR.O) is -3.73, compared to its 5-year average forward P/E of -5.22. For a more detailed relative valuation and DCF analysis to assess Capricor Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.22

Current PE

-3.73

Overvalued PE

5.84

Undervalued PE

-16.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.05

Current EV/EBITDA

-3.03

Overvalued EV/EBITDA

17.00

Undervalued EV/EBITDA

-27.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

185.01

Current PS

7.95

Overvalued PS

534.04

Undervalued PS

-164.01

Financials

Annual

Quarterly

FY2025Q2

YoY :

-100.00%

0.00

Total Revenue

FY2025Q2

YoY :

+139.14%

-27.72M

Operating Profit

FY2025Q2

YoY :

+135.56%

-25.91M

Net Income after Tax

FY2025Q2

YoY :

+62.86%

-0.57

EPS - Diluted

FY2025Q2

YoY :

+74.40%

-21.57M

Free Cash Flow

FY2025Q2

YoY :

-100.00%

N/A

Gross Profit Margin - %

FY2025Q2

YoY :

+217.05%

-420.98

FCF Margin - %

FY2025Q2

YoY :

-100.00%

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

15.0M

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

98.4K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

86.3K

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

15.0M

USD

Months

CAPR News & Events

Events Timeline

2025-08-18 (ET)

2025-08-18

09:03:04

Capricor reports initial participants administered in Phase 1 trial of StealthX

2025-08-11 (ET)

2025-08-11

16:48:07

Capricor Therapeutics reports Q2 EPS (57c), consensus (48c)

2025-08-11

09:01:23

Video: Nvidia, AMD said to pay U.S. 15% of revenue from China chip sales

News

8.0

08-21NASDAQ.COM

Significant Options Activity on Thursday: ETSY, AMGN, CAPR

7.0

08-21Globenewswire

Top Law Firm ROSEN Urges Capricor Therapeutics, Inc. Investors to Obtain Legal Representation Ahead of Key Deadline in Securities Class Action – CAPR

7.0

08-21Globenewswire

Bragar Eagel & Squire, P.C. Encourages XPLR Infrastructure, Centene, Biohaven, and Capricor Investors to Explore Their Rights in Class Action Lawsuits